Amalgamated Bank Uni Qure N.V. Transaction History

Amalgamated Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$11.12 - $22.2 $2,691 - $5,372	-242 Reduced 1.87%	12,721 $145,000
Q1 2023 May 02, 2023	SELL	$18.7 - $23.07 $7,274 - $8,974	-389 Reduced 2.91%	12,963 $261,000
Q3 2022 Nov 09, 2022	BUY	$16.98 - $25.54 $27,252 - $40,991	1,605 Added 13.66%	13,352 $250,000
Q2 2022 Aug 15, 2022	BUY	$13.15 - $20.45 $526 - $818	40 Added 0.34%	11,747 $219,000
Q1 2022 Aug 25, 2022	BUY	$14.54 - $21.5 $170,219 - $251,700	11,707 New	11,707 $212,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.